We could not find any results for:
Make sure your spelling is correct or try broadening your search.
HONG KONG -- (Marketwire) -- 02/07/12 -- Today, www.BollingerReport.com introduced featured coverage of Inhibitex, Inc. (NASDAQ: INHX) and Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX). Full...
Bristol's 4Q earnings fall short of Street view --Weaker-than-expected Plavix sales, higher expenses factor into shortfall --Bristol says newer drugs will help cushion impact of Plavix patent loss...
By Peter Loftus Of DOW JONES NEWSWIRES Bristol-Myers Squibb Co.'s (BMY) fourth-quarter profit surged 76% on lower tax provisions, while rising sales of anti-infective drugs and a new skin-cancer...
Bristol-Myers Squibb Company’s (BMY) fourth quarter 2011 earnings (excluding special items) of $0.53 per share fell short of the Zacks Consensus Estimate by $0.02. Adjusted earnings in...
Pharmaceutical giant Bristol-Myers Squibb Company (BMY) is all set to unveil its fourth quarter and full year 2011 results on January 26, 2012 before the start of trading. The Zacks...
For Immediate Release Chicago, IL – January 20, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss...
Gilead Sciences, Inc. (GILD) announced recently that it has completed its previously announced agreement to buy Pharmasset, Inc, a maker of drugs for the treatment of chronic hepatitis C virus...
NEW YORK, NY -- (Marketwire) -- 01/13/12 -- Levi & Korsinsky notifies investors of Inhibitex, Inc. ("Inhibitex" or the "Company") (NASDAQ: INHX) of claims of breaches of fiduciary duty and other...
Potentially Unfair Tender Offer for Inhibitex Triggers Shareholder-Claim Investigation by Securities Class Action Lawyers at Goldfarb Branham LLP PR Newswire DALLAS, Jan. 11, 2012 DALLAS...
Merck & Co. (MRK) will consider making acquisitions as part of its strategy to develop the next generation of hepatitis C treatments, the drug maker's research chief said Tuesday. The search...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions